Summary
ZLABN Chart
Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Christine Chiou - Senior VP & Head of Investor Relations Joshua L. Smiley - President & COO Rafael G.
Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings
The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zai Lab Ltd. Dividends
Zai Lab Ltd. Earnings
| 11 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 11 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 11 Aug 2025 Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 11 Nov 2025 (In 2 months) Date | | - Cons. EPS | - EPS |
| 11 Aug 2025 Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 Date | | - Cons. EPS | - EPS |
| 7 Aug 2025 Date | | - Cons. EPS | - EPS |
Zai Lab Ltd. (ZLABN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Zai Lab Ltd. ever had a stock split?
Zai Lab Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Ying Du CEO | XMEX Exchange | US98887Q1040 ISIN |
| CN Country | 1,869 Employees | - Last Dividend | - Last Split | 20 Sep 2017 IPO Date |
Overview
Zai Lab Limited is a biopharmaceutical company founded in 2013, dedicated to discovering, developing, and commercializing a broad range of therapies. The company focuses on treating a variety of conditions including oncology, autoimmune disorders, infectious diseases, and neuroscience disorders. Headquartered in Shanghai, China, Zai Lab has established multiple license and collaboration agreements with leading pharmaceutical companies worldwide to expand its product portfolio and research capabilities. These collaborations enable the company to leverage revolutionary technologies and compounds to address unmet medical needs in various therapeutic areas.
Products and Services
Zai Lab Limited's product pipeline includes:
- Zejula: An orally administered poly polymerase 1/2 inhibitor used for treating cancer.
- Optune: A novel cancer therapy utilizing electric fields tuned to specific frequencies aimed at disrupting the growth of tumor cells.
- NUZYRA: A treatment option for acute bacterial skin and skin structure infections, as well as community-acquired bacterial pneumonia.
- Qinlock: Designed for the treatment of gastrointestinal stromal tumors.
- VYVGART: A human IgG1 antibody fragment targeting myasthenia gravis.
- Tumor Treating Fields (TTFields): A portable device that delivers electric fields for treating tumors, developed in collaboration with NovoCure.
- Repotrectinib: A tyrosine kinase inhibitor targeting ROS1 and TRK A/B/C in cancer patients, under development in collaboration with BMS.
- Tisotumab vedotin: An antibody-drug conjugate for cancer treatment, developed in partnership with BMS.
- Adagrasib: A compound targeting KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer, developed in collaboration with Mirati.
- Bemarituzumab: Focused on treating gastric and gastroesophageal junction cancer patients, in partnership with Amgen.
- Sulbactam/Durlobactam: A combination therapy for serious infections caused by Acinetobacter, developed in collaboration with Innoviva.
- KarXT: Aimed at treating psychiatric and neurological conditions, under development in collaboration with Karuna.
In addition to these products, Zai Lab actively engages in research and development through collaborations with companies such as Tesaro, Inc., Deciphera, Paratek Bermuda Ltd., and argenx to enrich its pipeline and enhance treatment options available to patients worldwide.
Contact Information
